



(19)

Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 0 797 999 A2

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:
01.10.1997 Bulletin 1997/40

(51) Int Cl.⁶ **A61K 38/22**
// C07K14/575, C12N15/16

(21) Application number: 97301996.3

(22) Date of filing: 24.03.1997

(84) Designated Contracting States:
AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL
PT SE
Designated Extension States:
RO

- Edwards, Mary Joanna
Indianapolis, Indiana 46206 (US)
- Plick, Michael John
Ashford, Connecticut 06278 (US)
- Rineis, Joseph Vincent, Jr.
Brownsburg, Indiana 46112 (US)

(30) Priority: 28.03.1996 US 14177
05.04.1996 US 14961

(71) Applicant: ELI LILLY AND COMPANY
Indianapolis, Indiana 46286 (US)

(74) Representative: Hudson, Christopher Mark et al
Lilly Industries Limited
European Patent Operations
Erl Wood Manor
Windsorham Surrey GU20 6PH (GB)

(72) Inventors:
• Beale, John Michael
Indianapolis, Indiana 46278-1863 (US)

Remarks:

The applicant has subsequently filed a sequence listing and declared, that it includes no new matter.

(54) Formulations of obesity protein

(57) The present invention provides lyophilized compositions of an obesity protein. The compositions demonstrate remarkable stability and ease of manufacture and, significantly, are useful to prepare, stable pharmaceutical formulations useful for treating patients in need thereof. Thus, the invention further provides methods of using such formulations for the treatment of obesity, and disorders associated with obesity such as diabetes, cardiovascular disease and cancer.

macetual formulations useful for treating patients in need thereof. Thus, the invention further provides methods of using such formulations for the treatment of obesity, and disorders associated with obesity such as diabetes, cardiovascular disease and cancer.

EP 0 797 999 A2

BEST AVAILABLE COPY